Contraindication of Sumatriptan in Raynaud's Disease

Mechanism of Action

As a serotonin 5-HT1B/1D receptor agonist, sumatriptan induces vasoconstriction of blood vessels, which can affect both intracranial and peripheral vascular smooth muscle, leading to peripheral vasospasm in patients with Raynaud's disease 1

The standard approach to Raynaud's emphasizes vasodilation, with first-line therapy consisting of calcium channel blockers (particularly nifedipine), which directly oppose sumatriptan's vasoconstrictive effects, as recommended by the European League Against Rheumatism 2, 3, 4
Second-line options include PDE5 inhibitors and prostacyclin analogues—all vasodilators, aiming to maintain digital perfusion and prevent ischemic complications including digital ulcers and gangrene, as suggested by the European League Against Rheumatism 2, 4

The American Academy of Family Physicians confirms that sumatriptan is an absolute contraindication in patients with peripheral vascular disease or Raynaud's phenomenon due to the risk of serious vascular events, and recommends alternative non-vasoconstrictive options (such as NSAIDs or acetaminophen) for acute migraine treatment in these patients 5